Ampio Pharmaceuticals, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024004090 Filed on March 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q3

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.089M $6.398M
YoY Change -67.68% -62.25%
Cash & Equivalents $4.100M $6.400M
Short-Term Investments
Other Short-Term Assets $512.0K $718.0K
YoY Change -24.26% -47.74%
Inventory $215.0K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.736M $7.646M
YoY Change -56.97% -58.27%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $5.736M $7.646M
Total Long-Term Assets $0.00 $0.00
Total Assets $5.736M $7.646M
YoY Change -57.79% -59.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $750.0K $459.0K
YoY Change 673.2% 110.55%
Accrued Expenses $1.230M $1.812M
YoY Change 12.33% -51.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.376M $2.271M
YoY Change 99.33% -42.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.376M $2.271M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.376M $2.271M
YoY Change 32.07% -54.48%
SHAREHOLDERS EQUITY
Retained Earnings -$242.5M -$240.5M
YoY Change 3.68% 3.8%
Common Stock $245.9M $245.8M
YoY Change 0.06% 0.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.360M $5.375M
YoY Change
Total Liabilities & Shareholders Equity $5.736M $7.646M
YoY Change -57.79% -59.41%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001411906
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
833430
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
804674
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-35182
CY2023 dei Entity Registrant Name
EntityRegistrantName
AMPIO PHARMACEUTICALS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0179592
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
9800 Mount Pyramid Court
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Englewood
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80112
CY2023 dei City Area Code
CityAreaCode
720
CY2023 dei Local Phone Number
LocalPhoneNumber
437-6500
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
AMPE
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
3400000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1135358
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 dei Auditor Name
AuditorName
Moss Adams LLP
CY2023 dei Auditor Location
AuditorLocation
Denver, Colorado
CY2023 dei Auditor Firm
AuditorFirmId
659
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4089000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12653000
CY2023Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
920000
CY2022Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
0
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
727000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
676000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5736000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13329000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
184000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
75000
CY2023Q4 us-gaap Assets
Assets
5736000
CY2022Q4 us-gaap Assets
Assets
13588000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2102000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
852000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
274000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2376000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1192000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
274000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
44000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1462000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-79000
CY2022 ampe Adjustments To Additional Paid In Capital Warrant Issued In Connection With Registered Direct Offering To Placement Agent
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithRegisteredDirectOfferingToPlacementAgent
-32000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
810113
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
753615
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
810113
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
753615
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27284000
CY2023Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
0
CY2022Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
289000
CY2023Q4 us-gaap Liabilities
Liabilities
2376000
CY2022Q4 us-gaap Liabilities
Liabilities
1799000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
833430
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
804674
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
245887000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
245728000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242527000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233939000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3360000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11789000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5736000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13588000
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2439000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8916000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7079000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11466000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1614000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
322000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-56000
CY2023 us-gaap Operating Expenses
OperatingExpenses
9574000
CY2022 us-gaap Operating Expenses
OperatingExpenses
22318000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
348000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
220000
CY2023 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
305000
CY2023 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
289000
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5761000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
942000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5981000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8632000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16337000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.66
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21.68
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.66
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-29.32
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
509000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16337000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11789000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
159000
CY2023 ampe Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
0
CY2023 ampe Temporary Equity Stock Redeemed During Period Shares
TemporaryEquityStockRedeemedDuringPeriodShares
0
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
0
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
98000
CY2023 ampe Adjustments To Additional Paid In Capital Stock Issued Issuance Costs At Market Equity Offering Program
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsAtMarketEquityOfferingProgram
98000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8632000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3360000
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023 us-gaap Profit Loss
ProfitLoss
-8632000
CY2022 us-gaap Profit Loss
ProfitLoss
-16337000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
159000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1462000
CY2023 ampe Share Based Payment Arrangement Forfeiture Restricted Stock
ShareBasedPaymentArrangementForfeitureRestrictedStock
0
CY2022 ampe Share Based Payment Arrangement Forfeiture Restricted Stock
ShareBasedPaymentArrangementForfeitureRestrictedStock
509000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1048000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1614000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
322000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-56000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023 ampe Gain From Elimination And Accretion Of Aro Obligation Net
GainFromEliminationAndAccretionOfAroObligationNet
289000
CY2022 ampe Gain From Elimination And Accretion Of Aro Obligation Net
GainFromEliminationAndAccretionOfAroObligationNet
-7000
CY2023 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
5000
CY2023 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2022 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5761000
CY2023 us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
920000
CY2022 us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
0
CY2023 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
51000
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1064000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1251000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3959000
CY2023 ampe Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-265000
CY2022 ampe Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-79000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8564000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21128000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2023 ampe Proceeds From Sale Of Common Stock In Connection With At Market Equity Offering Program
ProceedsFromSaleOfCommonStockInConnectionWithAtMarketEquityOfferingProgram
98000
CY2022 ampe Proceeds From Sale Of Common Stock In Connection With At Market Equity Offering Program
ProceedsFromSaleOfCommonStockInConnectionWithAtMarketEquityOfferingProgram
0
CY2023 ampe Payment Of Stock Issuance Costs At Market Equity Offering Program
PaymentOfStockIssuanceCostsAtMarketEquityOfferingProgram
98000
CY2022 ampe Payment Of Stock Issuance Costs At Market Equity Offering Program
PaymentOfStockIssuanceCostsAtMarketEquityOfferingProgram
0
CY2023 ampe Payment Of Stock Issuance Cost Registered Direct Offering Monetary
PaymentOfStockIssuanceCostRegisteredDirectOfferingMonetary
0
CY2022 ampe Payment Of Stock Issuance Cost Registered Direct Offering Monetary
PaymentOfStockIssuanceCostRegisteredDirectOfferingMonetary
32000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
79000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-111000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8564000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21239000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12653000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33892000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4089000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12653000
CY2023 ampe Commercial Insurance Premium Financing Agreement
CommercialInsurancePremiumFinancingAgreement
703000
CY2022 ampe Commercial Insurance Premium Financing Agreement
CommercialInsurancePremiumFinancingAgreement
1159000
CY2023 us-gaap Settlement Of Asset Retirement Obligations Through Noncash Payments Amount
SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount
0
CY2022 us-gaap Settlement Of Asset Retirement Obligations Through Noncash Payments Amount
SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount
282000
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
15
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions primarily include the Company’s projected current and long-term liquidity needs and availability and the insurance recovery receivable. The Company develops these estimates using its judgment based upon experience and the facts and circumstances known at the time.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the year ended December 31, 2023, the Company did not maintain balances in excess of the federally insured limits; however, during the year ended December 31, 2022, the Company maintained balances in excess of federally insured limits.</p>
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
136000
CY2023Q4 us-gaap Deposit Assets
DepositAssets
34000
CY2023Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
920000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1600000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
300000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242500000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4100000
CY2023Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
900000
CY2023Q4 ampe Unamortized Commercial Insurance Current
UnamortizedCommercialInsuranceCurrent
339000
CY2022Q4 ampe Unamortized Commercial Insurance Current
UnamortizedCommercialInsuranceCurrent
610000
CY2023Q4 ampe Nonclinical Trials Current
NonclinicalTrialsCurrent
215000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
34000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
32000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
727000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
676000
CY2023Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P10Y
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9429000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9245000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
184000
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1600000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1048000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
750000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
97000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
706000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
157000
CY2023Q4 ampe Accrued Manufacturing Development Expense Payable Current
AccruedManufacturingDevelopmentExpensePayableCurrent
274000
CY2023Q4 ampe Commercial Insurance Premiums Current
CommercialInsurancePremiumsCurrent
177000
CY2022Q4 ampe Commercial Insurance Premiums Current
CommercialInsurancePremiumsCurrent
189000
CY2023Q4 ampe Accrued Non Clinical And Clinical Trial Payable Current
AccruedNonClinicalAndClinicalTrialPayableCurrent
73000
CY2022Q4 ampe Accrued Non Clinical And Clinical Trial Payable Current
AccruedNonClinicalAndClinicalTrialPayableCurrent
89000
CY2023Q4 ampe Subtenant Security Deposit Payable Current
SubtenantSecurityDepositPayableCurrent
62000
CY2023Q4 ampe Franchise Taxes Payable Current
FranchiseTaxesPayableCurrent
22000
CY2022Q4 ampe Franchise Taxes Payable Current
FranchiseTaxesPayableCurrent
78000
CY2022Q4 ampe Property Taxes Payable Current
PropertyTaxesPayableCurrent
74000
CY2022Q4 ampe Accrued Severance Payable Current
AccruedSeverancePayableCurrent
143000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2102000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
852000
CY2023Q1 ampe Gain On Elimination Of Aro Obligation
GainOnEliminationOfAroObligation
294000
CY2023Q1 ampe Asset Retirement Obligation Non Cash Gain On Derecognition Of Aro
AssetRetirementObligationNonCashGainOnDerecognitionOfAro
289000
CY2023Q1 ampe Loss On Derecognition Of Aro Asset
LossOnDerecognitionOfAroAsset
5000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
280000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
280000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
274000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
274000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
113000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
221000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53263
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
318.80
CY2022 ampe Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P3Y9M18D
CY2023 ampe Class Of Warrant Or Rights Forfeited Expired Or Cancelled
ClassOfWarrantOrRightsForfeitedExpiredOrCancelled
17179
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36084
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
316.28
CY2023 ampe Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P2Y9M7D
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36084
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
316.28
CY2023 ampe Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P2Y9M7D
CY2023 ampe Number Of Warrants Issued Or Exercised
NumberOfWarrantsIssuedOrExercised
0
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
44000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
44000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000.0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000.0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
833430
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12291
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36084
CY2023Q4 ampe Common Stock Shares Authorized Available Remaining Shares
CommonStockSharesAuthorizedAvailableRemainingShares
297918195
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1250000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14873
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
299.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M28D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2582
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
352.49
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12291
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
288.12
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M21D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11652
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
288.14
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M26D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12291
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
12291
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
288.12
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y9M21D
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
159000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
953000
CY2023 ampe Unrecognized Share Based Compensation Expenses
UnrecognizedShareBasedCompensationExpenses
28000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.034
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.040
CY2023 ampe Effective Income Tax Rate Reconciliation Registered Offering Loss And Warrant Expenses Rate
EffectiveIncomeTaxRateReconciliationRegisteredOfferingLossAndWarrantExpensesRate
0.000
CY2022 ampe Effective Income Tax Rate Reconciliation Registered Offering Loss And Warrant Expenses Rate
EffectiveIncomeTaxRateReconciliationRegisteredOfferingLossAndWarrantExpensesRate
-0.072
CY2023 ampe Effective Income Tax Rate Reconciliation Change In State Deferred Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInStateDeferredTaxRate
0.000
CY2022 ampe Effective Income Tax Rate Reconciliation Change In State Deferred Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInStateDeferredTaxRate
0.015
CY2023 ampe Effective Income Tax Rate Reconciliation Expiration Of Tax Attribute Carryforwards
EffectiveIncomeTaxRateReconciliationExpirationOfTaxAttributeCarryforwards
0.003
CY2022 ampe Effective Income Tax Rate Reconciliation Expiration Of Tax Attribute Carryforwards
EffectiveIncomeTaxRateReconciliationExpirationOfTaxAttributeCarryforwards
0.006
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.233
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.261
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
3000
CY2022Q4 ampe Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Right Of Use Asset
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRightOfUseAsset
18000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
67000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
150000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
51902000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
50196000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
424000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
459000
CY2023Q4 us-gaap Deferred Tax Assets Unrealized Losses On Trading Securities
DeferredTaxAssetsUnrealizedLossesOnTradingSecurities
768000
CY2022Q4 us-gaap Deferred Tax Assets Unrealized Losses On Trading Securities
DeferredTaxAssetsUnrealizedLossesOnTradingSecurities
768000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
606000
CY2023Q4 ampe Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Warrants
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWarrants
65000
CY2022Q4 ampe Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Warrants
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWarrants
65000
CY2023Q4 ampe Deferred Tax Assets Capitalized Development Costs
DeferredTaxAssetsCapitalizedDevelopmentCosts
3177000
CY2022Q4 ampe Deferred Tax Assets Capitalized Development Costs
DeferredTaxAssetsCapitalizedDevelopmentCosts
2093000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations
68000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56404000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54391000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
212000000.0
CY2023Q4 ampe Operating Loss Carryforward Carries Forward Indefinitely
OperatingLossCarryforwardCarriesForwardIndefinitely
81500000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-8632000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-16337000
CY2022 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-5761000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8632000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22098000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
810113
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
753615
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
810113
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
753615
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.66
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21.68
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.66
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-29.32
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
48822
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
68800
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
5000
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
67000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1315900

Files In Submission

Name View Source Status
0001558370-24-004090-index-headers.html Edgar Link pending
0001558370-24-004090-index.html Edgar Link pending
0001558370-24-004090.txt Edgar Link pending
0001558370-24-004090-xbrl.zip Edgar Link pending
ampe-20231231.xsd Edgar Link pending
ampe-20231231x10k.htm Edgar Link pending
ampe-20231231x10k004.jpg Edgar Link pending
ampe-20231231xex31d1.htm Edgar Link pending
ampe-20231231xex31d2.htm Edgar Link pending
ampe-20231231xex32d1.htm Edgar Link pending
ampe-20231231x10k_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
ampe-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ampe-20231231_cal.xml Edgar Link unprocessable
ampe-20231231_def.xml Edgar Link unprocessable
ampe-20231231_pre.xml Edgar Link unprocessable